Grifols Shares Are Trading Higher After the Company's Biotest Received FDA Approval for Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies.
Grifols Shares Are Trading Higher After the Company's Biotest Received FDA Approval for Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies.
基立福股價上漲，因爲該公司的生物試劑Biotest獲得了FDA批准，用於治療原發性免疫缺陷。
Grifols Shares Are Trading Higher After the Company's Biotest Received FDA Approval for Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies.
基立福股價上漲，因爲該公司的生物試劑Biotest獲得了FDA批准，用於治療原發性免疫缺陷。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。